N-methyl-D-aspartate antagonists: Ready for clinical trial in brain ischemia?

G. W. Albers, M. P. Goldberg, D. W. Choi

Research output: Contribution to journalArticle

215 Citations (Scopus)

Abstract

Antagonists of the N-methyl-D-aspartate (NMDA) subclass of glutamate receptors may offer a new approach for the treatment of ischemic brain injury. This strategy is supported by a well-developed scientific foundation and encouraging results in a variety of in vivo and in vitro experimental models. Several specific antagonists, including MK-801, dextrorphan, dextromethorphan, and ketamine, have already been used at low doses in humans for other indications and are potential candidates for Phase I clinical trials.

Original languageEnglish (US)
Pages (from-to)398-403
Number of pages6
JournalAnnals of Neurology
Volume25
Issue number4
StatePublished - 1989

Fingerprint

Dextrorphan
Dextromethorphan
Clinical Trials, Phase I
Dizocilpine Maleate
Glutamate Receptors
Ketamine
N-Methylaspartate
Brain Ischemia
Brain Injuries
Theoretical Models
Clinical Trials
In Vitro Techniques

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

N-methyl-D-aspartate antagonists : Ready for clinical trial in brain ischemia? / Albers, G. W.; Goldberg, M. P.; Choi, D. W.

In: Annals of Neurology, Vol. 25, No. 4, 1989, p. 398-403.

Research output: Contribution to journalArticle

@article{7d057e8095214ac8bc7b33fc29980dc6,
title = "N-methyl-D-aspartate antagonists: Ready for clinical trial in brain ischemia?",
abstract = "Antagonists of the N-methyl-D-aspartate (NMDA) subclass of glutamate receptors may offer a new approach for the treatment of ischemic brain injury. This strategy is supported by a well-developed scientific foundation and encouraging results in a variety of in vivo and in vitro experimental models. Several specific antagonists, including MK-801, dextrorphan, dextromethorphan, and ketamine, have already been used at low doses in humans for other indications and are potential candidates for Phase I clinical trials.",
author = "Albers, {G. W.} and Goldberg, {M. P.} and Choi, {D. W.}",
year = "1989",
language = "English (US)",
volume = "25",
pages = "398--403",
journal = "Annals of Neurology",
issn = "0364-5134",
publisher = "John Wiley and Sons Inc.",
number = "4",

}

TY - JOUR

T1 - N-methyl-D-aspartate antagonists

T2 - Ready for clinical trial in brain ischemia?

AU - Albers, G. W.

AU - Goldberg, M. P.

AU - Choi, D. W.

PY - 1989

Y1 - 1989

N2 - Antagonists of the N-methyl-D-aspartate (NMDA) subclass of glutamate receptors may offer a new approach for the treatment of ischemic brain injury. This strategy is supported by a well-developed scientific foundation and encouraging results in a variety of in vivo and in vitro experimental models. Several specific antagonists, including MK-801, dextrorphan, dextromethorphan, and ketamine, have already been used at low doses in humans for other indications and are potential candidates for Phase I clinical trials.

AB - Antagonists of the N-methyl-D-aspartate (NMDA) subclass of glutamate receptors may offer a new approach for the treatment of ischemic brain injury. This strategy is supported by a well-developed scientific foundation and encouraging results in a variety of in vivo and in vitro experimental models. Several specific antagonists, including MK-801, dextrorphan, dextromethorphan, and ketamine, have already been used at low doses in humans for other indications and are potential candidates for Phase I clinical trials.

UR - http://www.scopus.com/inward/record.url?scp=0024559799&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024559799&partnerID=8YFLogxK

M3 - Article

C2 - 2565699

AN - SCOPUS:0024559799

VL - 25

SP - 398

EP - 403

JO - Annals of Neurology

JF - Annals of Neurology

SN - 0364-5134

IS - 4

ER -